Zydus gets USFDA nod for Metoprolol Tartrate Tablets USP in 25, 50 & 100 mg

Zydus gets USFDA nod for Metoprolol Tartrate Tablets USP in 25, 50 & 100 mg

Zydus Lifesciences Ltd has been granted final authorization by the United States Food and Drug Administration (USFDA) to produce and market Metoprolol Tartrate Tablets USP, in 25 mg, 50 mg, and 100 mg strengths.

This medication, which is also known as Lopressor, is used alone or in conjunction with other drugs to manage high blood pressure. It helps in preventing strokes, heart attacks, and kidney issues by lowering high blood pressure. It is also utilized to treat angina, a type of chest pain, and to improve the likelihood of survival after a heart attack. Metoprolol falls under the group of beta-blockers, which works by restricting the activity of particular natural chemicals in the body, including epinephrine, on the heart and blood vessels, thus decreasing the heart rate, blood pressure, and strain on the heart.

Zydus will manufacture the drug at its formulation manufacturing facility located in Baddi, Himachal Pradesh, India. The annual sales of Metoprolol Tartrate Tablets USP, 25 mg, 50 mg, and 100 mg in the United States is around USD 45.2 million, according to IQVIA MAT Feb. 2023.

The company has received a total of 364 approvals and has submitted more than 440 ANDAs since the beginning of the filing process in the financial year 2003-04. This new approval will aid the firm in extending its market reach while also providing better treatment options to the individuals dealing with high blood pressure and other related medical conditions.

About Zydus Lifesciences:

Zydus Lifesciences Ltd, formerly recognized as Cadila Healthcare Limited, is a leading Indian multinational pharmaceutical firm located in Ahmedabad that specializes in producing generic medications. In 2020, the company ranked 100th on the Fortune India 500 list, solidifying its position as a prominent player in the pharmaceutical sector.

For More Latest News Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *